Mathis Grossmann
Overview
Explore the profile of Mathis Grossmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
176
Citations
2685
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wittert G, Robledo K, Handelsman D, Inder W, Stuckey B, Yeap B, et al.
J Clin Endocrinol Metab
. 2025 Feb;
PMID: 39928571
Context: The combined effects of testosterone treatment and lifestyle intervention on sexual function in men at high risk of type 2 diabetes are unclear. Objective: To assess the effect of...
2.
Grossmann M, Robledo K, Daniel M, Handelsman D, Inder W, Stuckey B, et al.
J Clin Endocrinol Metab
. 2025 Jan;
PMID: 39883545
No abstract available.
3.
Robledo K, Marschner I, Grossmann M, Handelsman D, Yeap B, Allan C, et al.
Eur J Endocrinol
. 2024 Dec;
192(1):15-24.
PMID: 39720906
Objective: We have shown that men aged 50 years+ at high risk of type 2 diabetes treated with testosterone together with a lifestyle program reduced the risk of type 2...
4.
Nicholls T, Hoermann R, Wootton E, Mansouri N, Stevens M, Vo H, et al.
J Clin Endocrinol Metab
. 2024 Nov;
PMID: 39586313
Objectives: To determine the relationship between ambient air temperature and the incidence of hyponatraemia in a heat-prone region. Design And Setting: We conducted a retrospective study that correlated serum sodium...
5.
Healy R, Patten R, Bauer C, Woessner M, Bourke M, Grossmann M, et al.
Sports Med Open
. 2024 Oct;
10(1):117.
PMID: 39467940
Background: Obesity and type 2 diabetes (T2D) are associated with alterations in testosterone concentrations. While evidence indicates that aerobic training can influence testosterone in healthy populations or females with hyperandrogenism,...
6.
Ramchand S, Seeman E, Hoermann R, Ghasem-Zadeh A, Grossmann M
J Clin Oncol
. 2024 Oct;
43(2):237-238.
PMID: 39365962
No abstract available.
7.
Grossmann M
Curr Opin Endocrinol Diabetes Obes
. 2024 Sep;
31(6):249-256.
PMID: 39311216
Purpose Of Review: Testosterone replacement therapy for men with organic hypogonadism due to medical disease of the hypothalamic-pituitary-testicular (HPT) axis is uncontroversial. In these men, testosterone replacement replaces the deficient...
8.
de Silva N, Papanikolaou N, Grossmann M, Antonio L, Quinton R, Anawalt B, et al.
Lancet Diabetes Endocrinol
. 2024 Aug;
12(10):761-774.
PMID: 39159641
Organic male hypogonadism due to irreversible hypothalamic-pituitary-testicular (HPT) pathology is easily diagnosed and treated with testosterone-replacement therapy. However, controversy surrounds the global practice of prescribing testosterone to symptomatic men with...
9.
Grossmann M, Wittert G
Ann N Y Acad Sci
. 2024 Jul;
1538(1):45-55.
PMID: 39039746
In epidemiological studies, lowered serum testosterone concentrations are common in men with obesity, prediabetes, and established type 2 diabetes (T2D). In men with prediabetes, lowered serum testosterone also predicts a...
10.
Ramchand S, Ghasem-Zadeh A, Hoermann R, White S, Yeo B, Francis P, et al.
J Clin Oncol
. 2024 Jul;
:JCO2302309.
PMID: 38954783
Purpose: Suppression of ovarian function and aromatase inhibition (AI) increases disease-free survival in premenopausal women with estrogen receptor (ER)-positive early-stage breast cancer but accelerates bone loss. We therefore hypothesized that...